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Plasma Concentration of SCUBE1, a Novel
Platelet Protein, Is Elevated in Patients With
Acute Coronary Syndrome and Ischemic Stroke
Dao-Fu Dai, MD,*† Peterus Thajeb, MD,‡§ Cheng-Fen Tu, MS,¶ Fu-Tien Chiang, MD, PHD,*
Chien-Hsiun Chen, PHD,¶ Ruey-Bing Yang, PHD,¶ Jin-Jer Chen, MD*¶
Taipei, Taiwan; and Manoa, Hawaii
Objectives This study investigates the potential application of plasma SCUBE1 [signal peptide–CUB (complement C1r/C1s,
Uegf, and Bmp1)–EGF (epidermal growth factor)-like domain-containing protein 1] as a biomarker of platelet
activation in acute coronary syndrome (ACS) and acute ischemic stroke (AIS).
Background Platelet activation plays a crucial role in ACS and AIS. Platelet stimulation is associated with increased plasma
concentration of SCUBE1, a novel platelet-endothelial secreted protein identified in our previous study.
Methods Plasma concentrations of SCUBE1 from 40 ACS and 40 AIS patients were measured by enzyme-linked immuno-
adsorbent assay and compared with the levels of 40 healthy control subjects and 83 chronic coronary artery dis-
ease (CAD) patients. Two-dimensional electrophoresis followed by Western blotting was used to characterize
SCUBE1 protein in patients’ plasma.
Results Plasma SCUBE1 concentration was virtually undetectable in healthy control subjects and CAD patients, but was
significantly higher in ACS and AIS patients (median  205 and 95.1 ng/ml, respectively, p  0.01). The in-
crease in plasma SCUBE1 was detectable in the plasma as early as 6 h after the onset of symptoms and re-
mained detectable up to 84 h. Plasma SCUBE1 concentration is an independent predictor of stroke severity
based on National Institutes of Health Stroke Scale (  3.18, p  0.001). Furthermore, smaller SCUBE1 frag-
ments were detected in ACS patients’ plasma, suggesting that plasma SCUBE1 might subject to a proteolytic
regulation under pathological conditions.
Conclusions Plasma SCUBE1 concentration is significantly elevated in ACS and AIS but not CAD patients. Plasma SCUBE1 is
a potential biomarker of platelet activation in acute thrombotic disease. (J Am Coll Cardiol 2008;51:2173–80)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.060h
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he have previously identified a novel family of secreted,
urface-anchored proteins by various genomic approaches
1,2). These proteins harbor an array of signal peptide,
omplement proteins C1r/C1s, Uegf, and Bmp1 (CUB),
nd epidermal growth factor (EGF)-like domains and
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xcellence of Universities Grant 91-B-FA09-2-4, National Science Council Grants
3-2320-B-001-048, 97-2752-B-006-003-PAE, and 97-2752-B-001-002-PAE,
nd Institute of Biomedical Sciences Grant IBMS-CRC96-P01.e
Manuscript received October 25, 2007; revised manuscript received December 19,
007, accepted January 7, 2008.ence are termed SCUBEs. Three distinct members of
CUBE, namely SCUBE1 to 3, have been described in
uman, mouse, and zebrafish (3– 6). They share common
rotein domains, consisting of an amino-terminal signal
eptide, 9 copies of EGF-like repeats, a spacer region
ith multiple potential N-glycosylation sites, and a CUB
omain at the carboxyl terminus (1,2).
See page 2181
We and others have shown that SCUBE1 is expressed
uring mouse development as well as in adult endothelial
ells (1,2,7). When overexpressed in human embryonic
idney (HEK)-293T cells, recombinant SCUBE1 protein is
secreted glycoprotein that forms oligomers tethered to the
ell surface (1). Our recent study found that SCUBE1 is
ighly expressed in platelets, at a level higher than in
ndothelial cells. These molecules are stored within the
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translocated to the platelet sur-
face upon activation by thrombin,
proteolytically released as smaller
soluble fragments, and incorpo-
rated into thrombus (8). Further-
more, immunohistochemistry re-
vealed the deposition of SCUBE1
in subendothelial matrix of human
advanced atherosclerotic lesions.
Since EGF-like repeats are well
known in mediating adhesive in-
teractions (9,10), our studies dem-
onstrated that the amino-terminal
EGF-like repeats of SCUBE1 are
able to enhance platelet adhesion
as well as ristocetin-induced plate-
let agglutination. Thus, SCUBE1
might function as a novel platelet-
endothelial adhesion molecule and
play pathological roles in cardio-
vascular biology (8).
Platelet activation and aggrega-
tion are well recognized as primary
reactions in arterial thrombosis
and, accordingly, are responsible
for the ischemic complications of
acute coronary syndromes (ACS)
(11,12) and acute ischemic stroke
(AIS) (13,14). Acute coronary
syndromes are initiated by plaque
rupture or erosion, with subse-
quent platelet activation and
hrombus formation. The importance of platelet activation
n the pathogenesis of these atherothrombotic complica-
ions was definitely shown by the application of antiplatelet
herapy as the most important management in ACS and
IS patients (12,15–18).
We hypothesize that plasma SCUBE1 could be a good
iomarker of platelet activation in acute atherothrombotic
iseases. The present study was designed to compare the
lasma concentrations of SCUBE1 in normal control sub-
ects, in patients with chronic coronary artery disease
CAD), ACS, and AIS. In addition, biochemical charac-
erization of plasma SCUBE1 protein was performed.
ethods
his study was approved by institutional review boards of
ur hospitals, and written informed consents were obtained
rom the participants. The investigation conforms with
rinciples outlined in the Declaration of Helsinki (19).
tudy population. We recruited 83 subjects with chronic
AD and 40 subjects with ACS from 152 consecutive
atients undergoing cardiac catheterization, as well as 40 of
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
AIS  acute ischemic
stroke
CAD  coronary artery
disease
CUB  complement
proteins C1r/C1s, Uegf,
and Bmp1
EGF  epidermal growth
factor
LAT  large-vessel
atherothrombotic (stroke)
NIHSS  National
Institutes of Health Stroke
Scale
NSTEMI  non–ST-segment
elevation myocardial
infarction
SCUBE1  signal peptide–
complement proteins
C1r/C1s, Uegf, and
Bmp1–epidermal growth
factor-like domain
containing protein 1
STEMI  ST-segment
elevation myocardial
infarction
TIA  transient ischemic
attack
UA  unstable angina6 consecutive patients with AIS from 2 medical centers in paiwan. For control subjects, we recruited 40 healthy
ubjects visiting for health check-up, frequency matched for
ender and age to the ACS patients. During hospitalization,
ll participants had a record of medical history of diabetes,
ypertension, smoking, hypercholesterolemia (total choles-
erol 200 mg/dl and/or low-density lipoprotein choles-
erol 160 mg/dl), prior antiplatelet and statin use.
ecruitment and exclusion criteria. Four groups of sub-
ects were studied. Group I (CAD) included 83 subjects
ith chronic stable angina and angiography-proven CAD,
efined as at least 1 coronary artery stenosis of 50%
uminal diameter narrowing. Group II (ACS) included 40
atients with ST-segment elevation myocardial infarction
STEMI), non–ST-segment elevation myocardial infarc-
ion (NSTEMI), or high-risk unstable angina (UA) within
20 h of onset. ST-segment elevation myocardial infarction
nd NSTEMI were defined according to the consensus of
he American Heart Association/American College of Car-
iology. Unstable angina was defined as Braunwald class III
hest pain with significant electrocardiogram changes, in-
luding transient ST-segment depression or T inversion.
Group III (AIS) consisted of 40 patients with first acute
erebral infarction within 120 h of onset, including large-
essel atherothrombotic (LAT) stroke and small lacunar
nfarction. Acute ischemic stroke was defined as acute
resentation of focal neurological deficits in concordance
ith ischemic changes at corresponding areas by diffusion
eighted image and T2-weighted image of the brain
agnetic resonance imaging. Large-vessel atherothrom-
otic ischemic stroke was defined as acute cerebral infarc-
ion involving the trunk or branched vessels of the major
erebral arteries, whereas acute lacunar infarction was de-
ned as small infarction (20 mm3) in the areas supplied by
he penetrating arterioles (20–22). Six AIS patients were
xcluded because of evidence of old infarctions in 3 patients,
emorrhagic transformation of the infarctions in 2, and
o-existence of chronic subdural hemorrhage in the others.
o assess the severity of AIS, we evaluated the baseline
ational Institutes of Health Stroke Scale (NIHSS) (23).
roup IV (control subjects) included 40 healthy subjects
andomly selected from physical check-up department with-
ut history or clinical signs of chest pain or neurological
mpairment. They were matched with ACS subjects for
ender and age.
Exclusion criteria included idiopathic cardiomyopathies,
ignificant valvular heart disease, any malignancy, hemato-
ogic or rheumatologic disease, renal failure (serum creati-
ine 3), or liver diseases (elevated aminotransferases). At
he end of the study, we additionally recruited 19 patients
ith transient ischemic attack (TIA), defined as acute stroke
ymptoms that recovers within 24 h of onset, for post-hoc
omparison with acute LAT ischemic stroke patients.
lasma SCUBE1 and sCD40L assays. Heparinized blood
amples were centrifuged at 2,500 g and plasma was stored
t 80°C for further analysis. High-binding, flat-bottom
olypropylene 96-well plates (NUNC, Naperville, Illinois)
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June 3, 2008:2173–80 Plasma SCUBE1 Is Elevated in ACS and Strokeere coated overnight at 4°C with 50 l of anti-SCUBE1
onoclonal Ab #712 (5 g/ml) developed in our lab (8).
he coated plates were washed (0.05% Tween-20 in
hosphate-buffered saline), blocked (0.5% bovine serum
lbumin in phosphate-buffered saline), and incubated for
h with 50 l of recombinant SCUBE1 or plasma samples
n triplicate. After washing, a second horseradish
eroxidase-conjugated SCUBE1 mAb #701 (5 g/ml) was
ncubated for 1 h, then washed, and developed with tetra-
ethyl benzidine (KPL, Gaithersburg, Maryland) followed
y 1 N HCl. Then the absorbance at 450 nm was deter-
ined (SpectraMax 340PC, Molecular Devices, Sunnyvale,
alifornia). The minimum detection limit by this method
as 50 ng/ml. The concentrations of sCD40L were deter-
ined in heparinized plasma by enzyme-linked immuno-
dsorbent assay according to manufacturer’s protocol (R&D
ystems, Minneapolis, Minnesota). All assays were per-
ormed in batch by another investigator blinded to the
linical diagnoses. The intra-assay and interassay covariance
f both assays was 10%.
For Group II (ACS) and III (AIS) subjects, time from
nset of symptoms to blood withdrawal was recorded. To
nvestigate the serial changes of plasma SCUBE1, we
xamined 8 consecutive acute STEMI patients soon after
dmission to coronary care units, then every 12 h for 3 to 4
ays.
haracterization of plasma SCUBE1 and comparison
ith full-length SCUBE1. Total plasma protein was sep-
rated by 2-dimensional electrophoresis using nonlinear pI
-7 immobilized pH gradient strips for the first dimension
nd 10% acrylamide gels for the second dimension. The gels
ere transferred to polyvinylidene fluoride membranes and
tained with anti-SCUBE1 monoclonal antibody (MAb
01), followed by a secondary HRP-conjugated goat anti-
ouse antibody.
To confirm that full length SCUBE1 would be cleaved by
erum proteases, we overexpressed Flag.SCUBE1 in HEK-
93T cells in the presence or absence of 10% fetal bovine
erum in Dulbecco’s modified Eagle’s medium. After 48 h
f incubation, the medium was immunoprecipitated and
lotted with anti-Flag antibody to identify the secreted
lag-tagged SCUBE1. Two carboxyl-terminal deletion
utants D1 (lacking CUB domain) and D2 (further lacking
he spacer region) (1) were used as comparison.
tatistical analysis. The baseline characteristics of partic-
pants were analyzed according to case-control study design,
amely CAD versus control subjects, ACS versus control
ubjects, and AIS versus control subjects. Demographics
ere presented as mean  standard deviation for continu-
us variables and frequencies (percentages) for categorical
ariables. The chi-square test and the 2-sample t test were
sed to detect proportion differences and mean differences
etween cases and control subjects, respectively, as indepen-
ent samples.
The comparisons of plasma SCUBE1 concentrationetween cases and control subjects and among clinical cubtypes were carried out using nonparametric methods
or 2 reasons: 1) lower plasma SCUBE1 concentration
50 ng/ml) was undetectable; and 2) the distribution of
lasma SCUBE1 concentration was skewed to the right,
nd some extreme observations remained strongly influ-
ntial to the mean values. Therefore, we applied the
ilcoxon rank sum test to compare the plasma SCUBE1
oncentration between cases and control subjects and
ruskal-Wallis test for comparison among clinical sub-
ypes. To be conservative, we used 50 ng/ml to represent
ll values below the detection limit of 50 ng/ml for the
nalyses. Multiple comparisons were corrected with Bon-
erroni method for cases (CAD, ACS, AIS) versus
ontrol subjects (the original p values multiply by 3, at the
ignificant level of 0.05). Similar approach was applied
or the analysis of plasma sCD40L because the distribu-
ion was skewed and the lowest detection limit was 15
g/ml. The relationship between plasma SCUBE1 and
isease status as well as plasma sCD40L were further
valuated by using multiple linear regression models with
og-transformed plasma SCUBE1 as outcome variable,
hereas disease status, log-transformed plasma sCD40L,
nd all potential covariates as explanatory variables. From the
ull model 1, backward stepwise method with a value of p
.2 was applied to select important covariates to generate
he simplified final model, which adequately explained the
ull model, confirmed by likelihood ratio test.
To explore how plasma SCUBE1 concentration was
elated to the severity of acute stroke, we applied multiple
inear regressions with log-transformed SCUBE1 concen-
ration as an independent variable, predicting NIHSS,
ssumed as a continuous variable, and adjusted for the same
ovariates with backward selection method. To investigate
he relationship of plasma SCUBE1 concentration and
nset time, we plotted plasma SCUBE1 concentration of
CS and AIS patients versus onset time, and created serial
urves for 6 ACS cases. STATA (StataCorp, College
tation, Texas) version 8.0 was used for all statistical
alculation.
esults
aseline characteristics of study population. Baseline
haracteristics of patients in the 3 cases groups versus
ealthy control subjects are shown in Table 1. There were
o significant differences in age, gender, and platelet counts.
ll 3 groups had significantly higher levels of total choles-
erol and higher proportions of all conventional risk factors
s well as prior statin and antiplatelet use than healthy
ontrol subjects. Plasma triglyceride concentrations were
ignificantly higher in CAD and AIS patients, and plasma
reatinine levels were significantly higher in CAD and ACS
atients, when compared with those of control subjects. The
linical subtypes of each group were also shown.
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Plasma SCUBE1 Is Elevated in ACS and Stroke June 3, 2008:2173–80lasma SCUBE1 and sCD40L concentrations in cases
ersus controls. The median (25%, 75%) plasma SCUBE1
oncentration of subjects with CAD, ACS, and AIS were
0 (50, 50), 205 (67.6, 483.1), and 95.1 (50.0, 365.5) ng/ml,
espectively. Both ACS and AIS patients had significantly
igher plasma SCUBE1 than that in healthy control sub-
ects, whose plasma SCUBE1 was mostly below detection
imit (50 ng/ml), with both p values after Bonferroni
orrection 0.001 (Fig. 1A). Plasma SCUBE1 concentra-
ion in CAD patients was not significantly higher than
ontrol subjects. Meanwhile, plasma sCD40L concentration
f CAD, ACS, and AIS patients were 28 (19, 67), 37 (20,
7), and 15 (15, 32) pg/ml, respectively. Both CAD and
CS had significantly higher plasma sCD40L than those in
ormal control subjects, with the level of 15 (15, 36) pg/ml.
Table 2 shows multiple linear regression models predict-
ng plasma SCUBE1, adjusted for potential covariates. We
ound that both ACS and AIS were independent predictors
f elevated plasma SCUBE1 concentration. Older age tends
o decrease and smoking tends to increase plasma SCUBE1
oncentration, as shown in final model 1. Increasing plasma
CD40L is significantly associated with increasing plasma
CUBE1, shown by unadjusted Spearman rho  0.59 (p 
.005) as well as the multiple regression models (  0.32,
 0.001; R2  0.42).
ubgroup analysis of plasma SCUBE1 and sCD40L. Figure
B demonstrated the boxplots of both biomarkers stratified
y clinical subtypes. Subjects with acute LAT stroke had
ignificantly higher plasma SCUBE1 and sCD40L concen-
ration compared with those in small lacunar stroke patients,
oth p  0.01. Interestingly, LAT stroke also had higher
lasma SCUBE1 than TIA patients (p  0.01). Within the
Baseline Characteristics of Study Population
Table 1 Baseline Characteristics of Study P
Variables
Chronic CAD
(n  83)
Age, yrs 64.2 11.7
Men (%) 62.5
Diabetes, n (%) 39 (48.8)
Hypertension, n (%) 62 (77.5)
Smoking, n (%) 37 (46.3)
Hypercholesterolemia, n (%) 46 (57.5)
Prior statin use, n (%) 39 (47)
Prior antiplatelet use, n (%) 69 (83.1)
Clinical subtypes (%) 3VD: 43.8
2VD: 23.8
1VD: 32.5
Laboratory
Total cholesterol (mg/dl) 198 58*
Triglycerides (mg/dl) 173 126†
Plasma creatinine (mg/dl) 1.3 1.0†
Platelet counts (106/ml) 203 62
*p  0.001, †p  0.05 compared with control subjects.
AIS acute ischemic stroke; LAT large-vessel atherothrombotic st
lacunar stroke; STEMI  ST-segment elevation myocardial infarction
3VD  3-vessel-disease; other abbreviations as in Table 1.AD group, the number of stenotic vessels was neither Associated with plasma SCUBE1 nor with sCD40L con-
entration. Likewise, subjects with STEMI, NSTEMI, and
A did not differ significantly in plasma SCUBE1 and
CD40L concentration. However, these subgroup post-hoc
nalyses were based on small sample size, which had limited
tatistical power to detect differences of 2-fold.
lasma SCUBE1 concentration in relationship to onset
ime. Figure 2A showed the scatter plot of plasma
CUBE1 concentration corresponding to the onset time in
atients with ACS and LAT stroke. Plasma SCUBE1 was
etectable as early as 6 h after the onset of symptoms, and
ot later than 84 h, both in ACS and LAT stroke. This
endency was further supported by the serial measurement
f plasma SCUBE1 concentration in 6 of 8 patients with
cute STEMI (Fig. 2B). Peak values occur at 36 to 60 h
fter onset, and degraded not later than 96 h after onset.
wo other patients who received thrombolytic therapy with
ecombinant tissue plasminogen activator had undetectable
lasma SCUBE1 for the entire serial time measurement.
lasma SCUBE1 concentration and severity of acute
hrombotic complications. Multiple regression analysis
evealed that plasma SCUBE1 concentration was an inde-
endent predictor of NIHSS in LAT stroke patients, with
 3.3 (95% confidence interval 2.77 to 3.82, p  0.001;
2  0.75) (Table 2, model 2). There was no correlation
etween plasma SCUBE1 and single measurement of
lasma troponin I concentration in ACS patients (not
hown).
lasma SCUBE1 exists as proteolytic products of the
ull-length SCUBE1. To confirm and further characterize
CUBE1 in plasma, we performed 2-dimensional electro-
horesis followed by Western blot on plasma samples from
tion
ACS
 40)
AIS
(n  40)
Control Subjects
(n  40)
 11.8 63.2 14.5 61.3 13.8
65 65 62.5
(40.0) 23 (57.5) —
(70.0) 32 (80.0) —
(67.5) 20 (50.0) —
(55.0) 22 (55.0) —
(50) 15 (37.5) —
(65) 27 (67.5) —
MI: 40 LAT: 62.5
EMI: 45 SL: 37.5
15
 47* 210 52* 156 30
 85 184 102† 126 83
 1.1* 1.1 0.9 0.9 0.3
 63 238 72 215 63
STEMI non–ST-segment elevation myocardial infarction; SL small
unstable angina; 1VD  1-vessel-disease; 2VD  2-vessel-disease;opula
(n
61.2
16
28
27
22
20
26
STE
NST
UA:
196
148
1.5
220
roke; NCS patients with elevated SCUBE1. As shown in Figure
3
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June 3, 2008:2173–80 Plasma SCUBE1 Is Elevated in ACS and StrokeA, this approach identified an acidic (pI of 5.0) and a
eutral fragments (pI of 6.5) with molecular weight of
95 and 80 kDa, respectively, which are different from
ull-length SCUBE1 protein extracted from platelets, with
olecular weight of 135 kDa and the pI of 6.7 (1). It is
oteworthy that the 95-kDa fragment is the reminiscent of
hrombus-associated fragment described in our recent re-
ort (8).
otential proteolytic cleavage site is located in the spacer
egion. As seen in Figure 3B, under serum-free conditions,
he molecular weight of the secreted full-length SCUBE1
rotein is 135 kDa (1). However, in the presence of serum,
fraction of the secreted protein undergoes proteolysis by
Figure 1 Plasma SCUBE1 and sCD40L Concentration
in CAD, ACS, and Acute Stroke Patients
Plasma concentration of signal peptide–complement proteins C1r/C1s, Uegf,
and Bmp1–epidermal growth factor-like domain containing protein 1 (SCUBE1)
and sCD40L in cases (coronary artery disease [CAD], acute coronary syn-
dromes [ACS], acute ischemic stroke) versus healthy control subjects (A), and
in subgroup analyses (B). For SCUBE1, p  0.01 after Bonferroni correction in
ACS versus control subjects and acute ischemic stroke versus control sub-
jects. For sCD40L, *p  0.02, **p  0.01 after Bonferroni correction. LAT 
large-vessel atherothrombotic; NSTEMI  non–ST-segment elevation myocardial
infarction; SL  small lacunar stroke; STEMI  ST-segment elevation myocar-
dial infarction; TIA  transient ischemic attack; UA  unstable angina; VD 
vessel-disease.erum proteases, resulting in a cleaved fragment with theolecular weight of 65 kDa (Fig. 3B). This SCUBE1
ragment has a molecular weight between SCUBE1 D1 and
2 mutant products, suggesting that the possible cleavage
ite is somewhere within the spacer region.
iscussion
latelet aggregation has been well known as the culprit of
CS and AIS. Our recent study demonstrated that
CUBE1 was abundantly expressed in human platelets (8).
his novel protein was predominantly stored within the
latelet -granules and only negligible amount, if any, was
resent on the cell surface of resting platelets. Upon platelet
timulation, SCUBE1 was translocated to platelet surface,
leaved, and then released into plasma (8). In the present
tudy we demonstrated that plasma SCUBE1 was elevated
n ACS and acute LAT stroke patients, concomitant with
he increase in plasma sCD40L, suggesting platelets as the
rigin of plasma SCUBE1. This was further supported by
he finding of 2-dimensional electrophoresis followed by
estern blot, showing that plasma SCUBE1 exists as
Figure 2 Plasma SCUBE1 Concentration in Patients With
ACS and Acute LAT Stroke Versus Time After Onset
(A) Scatterplot of plasma SCUBE1 concentration. One point represents 1 sub-
ject. Plasma SCUBE1 was detected as early as 6 h after the onset of symp-
toms, but no later than 84 h, in both ACS and LAT. (B) Serial measurement of
plasma SCUBE1 concentration in 6 patients with acute STEMI treated with pri-
mary percutaneous coronary intervention. Peak values occur at 36 to 60 h
after onset, and degraded not later than 96 h. Abbreviations as in Figure 2.
s
S
P
t
p
i
C
g
u
s
p
i
e
fi
p
s
i
c
o
a
o
a
s
t
p
o
f
a
s
p
t
M
*
p
a
g
o
B
2178 Dai et al. JACC Vol. 51, No. 22, 2008
Plasma SCUBE1 Is Elevated in ACS and Stroke June 3, 2008:2173–80maller fragments, as proteolytic products of full-length
CUBE1 protein in platelets (8).
lasma SCUBE1: a novel biomarker of platelet activa-
ion in acute thrombotic diseases. As shown in Figure 1,
lasma SCUBE1 concentrations were significantly elevated
n ACS and acute LAT stroke patients, but not in chronic
AD patients. This complies with the fact that the patho-
enesis of chronic CAD is different from those of ACS. The
nstable plaques in ACS consisted of large lipid core with
evere inflammation, which ruptured and caused massive
latelet activation. In chronic CAD, the stable plaques
nvolved prominent smooth muscle proliferation, increased
xtracellular matrix synthesis that was covered by thick
brous caps, with less inflammation and subsequently less
laque ruptures. While platelets did play a role in athero-
clerosis, acute massive platelet activation was less common
n chronic stable CAD (11,24). Interestingly, of seven
hronic CAD patients with elevated plasma SCUBE1, we
bserved that 2 of them had coronary arteriovenous fistula,
nother 2 had relatively sluggish coronary flow, and the
ther 3 did not have any specific finding on coronary
ngiography.
In the subgroup analysis of AIS, LAT stroke but not
mall lacunar stroke had elevated plasma SCUBE1 concen-
ration. Large-vessel atherothrombotic stroke involved acute
latelet activation, while small lacunar stroke involved the
cclusion of small penetrating artery due to lipohyalinosis
rom sustained hypertension, with less evidence of platelet
ctivation (22). Our post-hoc analysis also showed that
ubjects with acute LAT stroke had significantly higher
lasma SCUBE1 than those with TIA, indicating a poten-
ultiple Regression Analyses
Table 2 Multiple Regression Analyses
Explanatory Variables Coefficient p Value
Model 1: predicting log SCUBE1 (full model)*†
CAD‡ 0.14 0.720
ACS‡ 1.08 0.011
Stroke‡ 1.04 0.009
Log sCD40L 0.32 0.001
Age 0.01 0.121
Smoking 0.37 0.091
Final Model 1: predicting log SCUBE1 (backward stepwise method)†
ACS‡ 1.15 0.001
Stroke‡ 1.10 0.001
Log sCD40L 0.32 0.001
Age 0.01 0.061
Smoking 0.35 0.056
Model 2: log SCUBE1 predicting NIHSS (backward stepwise method)†
Log SCUBE1 3.30 0.001
Age 0.01 0.168
Full model 1 also included gender, diabetes, hypertension, hypercholesterolemia, platelet counts,
rior antiplatelet and statin uses (all with a value of p  0.2); †R2 for full model 1; final model 1
nd model 2 were 0.41, 0.42, and 0.76, respectively; ‡normal control subjects as the reference
roup.
ACS  acute coronary syndromes; CAD  coronary artery disease; NIHSS  National Institutes
f Health stroke scale; SCUBE1  signal peptide–complement proteins C1r/C1s, Uegf, and
mp1–epidermal growth factor-like domain containing protein 1.ial application in the clinical setting to distinguish betweenFigure 3 Plasma SCUBE1 as Proteolytic Fragments
(A) Two-dimensional electrophoresis and Western blot of a representative
plasma sample of acute coronary syndromes patients probed with antisignal
peptide–complement proteins C1r/C1s, Uegf, and Bmp1–epidermal growth
factor-like domain containing protein 1 (SCUBE1) antibody. Two spots (arrow-
heads) represent the proteolytic fragments (MW  95 kDa, pI  5 and MW 
80 kDa, pI  6.5, respectively), different from the full-length SCUBE1 protein
(MW  135 kDa, pI  6.7, arrow). These 2 fragments have been seen in mul-
tiple acute coronary syndromes plasma samples. (B) The secreted SCUBE1
protein is cleaved in the presence of fetal bovine serum (FBS). The recombi-
nant Flag.SCUBE1 protein was produced in HEK-293T cells in the presence or
absence of FBS. Immunoprecipitation of Flag.SCUBE1 was followed by Western
blotting using anti-FLAG antibody. (C) Proteolytic cleavage within the spacer
region of the secreted SCUBE1. Recombinant Flag.SCUBE1 full-length (FL),
deletion mutants (D1 and D2) protein was compared with the cleaved SCUBE1
fragment. The positions of FL protein (arrow) or its cleaved fragments (arrow-
head) are indicated. (D) Domains of the SCUBE1 full-length and deletion
mutants. Arrow shows a putative protease cleavage site (RXXR) within the
spacer region. “Y” indicates potential N-linked glycosylation site. CUB  com-
plement proteins C1r/C1s, Uegf, and Bmp1 domain; E  EGF-like repeats;
SP  signal peptide.
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June 3, 2008:2173–80 Plasma SCUBE1 Is Elevated in ACS and Strokecute LAT stroke and TIA. Moreover, plasma SCUBE1
as independently correlated with plasma sCD40L (Table
, model 1), a marker of platelet activation as well as
nflammation. These findings support that plasma
CUBE1 is a biomarker of platelet activation during acute
hrombotic complications, such as in ACS and acute LAT
troke.
inetics of plasma SCUBE1 and its role as a prognostic
actor. The relatively slow kinetics of plasma SCUBE1
elease (Fig. 2) were comparable to many well-known
iomarkers in acute myocardial infarction, such as creatine
inase, troponins, lactate dehydrogenases, and myoglobins
25). In patients with acute platelet activation, plasma
CUBE1 was elevated as early as 6 h after onset, and
emained detectable for 3 to 4 days. This variation may
epend on the degree of platelet activation, the persistence
f platelet stimulants, the inherent activity of serum pro-
eases, as well as the modification from antiplatelet medi-
ations or thrombolytic agents. Indeed, we observed that 2
TEMI patients receiving thrombolytic therapy had unde-
ectable plasma SCUBE1 for the whole serial measurement.
hile plasma SCUBE1 may not be a sensitive marker of
ither ACS or stroke, it might be a good marker of platelet
ctivation in these acute thrombotic diseases.
Furthermore, plasma SCUBE1 concentration is an
ndependent predictor of NIHSS in patients with LAT
troke (Table 2, model 2). Baseline NIHSS is a reliable
ssessment of stroke severity, and well correlated with
troke prognosis (23).
lasma SCUBE1 as proteolytic fragments derived from
ctivated platelet. Plasma SCUBE1 in ACS patients exists
s smaller fragments (Fig. 3A). Consistent with this finding,
n-vitro study demonstrated that the secreted form of
CUBE1 was proteolytically cleaved by serum proteases to
elease the carboxyl-terminal CUB from the amino-
erminal portion of the EGF-like repeats (Fig. 3B). Further
apping by using a series of SCUBE1 deletion mutants
evealed that the potential proteolytic cleavage site is located
ithin the spacer region (Figs. 3C and 3D). However, it
emains to be established the precise cleavage site as well as
he identity of serum protease for SCUBE1. The presence
f multiple isoforms of SCUBE1 fragments suggests that
he cleavage is complexly regulated in the pathological
ettings of ACS and AIS. The proteolytic cleavage might
lso represent an activation mechanism as described for the
egulation of the CUB domain-containing secreted pro-
eins, like platelet-derived growth factor-C and -D (26–28).
ndeed, our recent data demonstrated that the amino-
erminal 9 copies of the EGF-like repeats function as an
dhesive module in mediating the platelet-matrix and
latelet-platelet interactions (8). These soluble EGF-like
omain fragments of SCUBE1, though alone did not
rigger platelet aggregation, could potentiate ristocetin-
nduced platelet agglutination. Ristocetin causes conforma-
ional change of von Willebrand factor and initiates the
inding of von Willebrand factor to platelet glycoprotein Ib,hen induces platelets agglutination, which is a fluid-phase
nalogy to platelet-subendothelial matrix adhesion (29).
tudy limitations. While this pilot study showed a prom-
sing result of plasma SCUBE1 as a biomarker of platelet
ctivation in acute thrombotic disease, it was based on a
elatively small sample size that had limited statistical power
o detect small differences in subgroup analyses. Moreover,
he current enzyme-linked immunoadsorbent assay method
or plasma SCUBE1 has a limited sensitivity of 50 ng/ml.
otential clinical applications. Though cardiac troponins
re excellent markers for detecting myocardial damage and
an easily distinguish acute myocardial infarction from UA,
owever, plasma SCUBE1 as a biomarker of platelet acti-
ation, in conjunction with cardiac troponins, might further
trengthen the diagnosis of UA and differentiate UA from
onspecific cause of acute chest pain. In addition, plasma
CUBE1 is also potentially useful to distinguish acute
troke and TIA as well as for risk stratification of acute LAT
troke patients. Further larger clinical studies are required to
alidate the clinical application of plasma SCUBE1 as a
arker of platelet activation, a prognostic biomarker, as well
s for monitoring response to therapy in patients with acute
hrombotic complications.
onclusions
n summary, this study is the first to demonstrate that
lasma SCUBE1 concentrations are elevated in patients
ith ACS and acute LAT stroke. Moreover, plasma
CUBE1 concentration is an independent predictor of
troke severity as assessed by NIHSS. The soluble plasma
CUBE1 derived from stimulated platelets through a pro-
eolytic cleavage that might play pathological roles by
acilitating the platelet adhesion/agglutination and, subse-
uently, thrombus formation.
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